Ignite Creation Date:
2024-07-17 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06500819
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-07-08
Brief Title:
Autologous B7-H3 Chimeric Antigen Receptor T Cells in RelapsedRefractory Solid Tumors
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Phase I Clinical Trial of Autologous B7-H3 Chimeric Antigen Receptor T Cells B7-H3CART in Children and Young Adults With Relapsed or Refractory Solid Tumor Expressing B7-H3 Target
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test the manufacturing feasibility and safety of intravenous IV administration of B7-H3CART in children and young adult subjects with relapsed andor refractory solid tumors expressing B7-H3 target using a standard 33 dose escalation design
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None